Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial
Aim of investigation. To determine efficacy and safety of budesonide and prednisolone at alcoholinduced hepatitis (AH) of severe course on development of inflammation and results of the functional hepatic tests, to estimate treatment response and short-term survival rate of patients.Material and met...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2013-09-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1219 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860174294614016 |
|---|---|
| author | I. I. Komkova M. V. Mayevskaya V. T. Ivashkin |
| author_facet | I. I. Komkova M. V. Mayevskaya V. T. Ivashkin |
| author_sort | I. I. Komkova |
| collection | DOAJ |
| description | Aim of investigation. To determine efficacy and safety of budesonide and prednisolone at alcoholinduced hepatitis (AH) of severe course on development of inflammation and results of the functional hepatic tests, to estimate treatment response and short-term survival rate of patients.Material and methods. Original study included 37 patients with acute AH, that have been selected from 3 medical centers and randomized in two groups. The first group included 17 patients (7 men, 10 women, mean age 46,53±11,01 years). Median of daily alcohol dose was 77 g; 25th and 75th percentiles were 55 and 96 g; duration of intake 13,41±8,55 years. Mean Maddrey index (MI) was 65,22 (37,2 to 145,4). The second group included 20 patients (16 men, 4 women, mean age was 46,5±11,89 years). A median of used alcohol consumption was 70,55 g/day (25th 75th percentiles were 37 and 88 g), duration of intake — 16,85±13,32 years. Mean MI – 58,11 (32,1 to 121,7). Groups were comparable for main clinical and laboratory features. In the first group oral budesonide 9 mg/day per os was applied, in the second – oral prednisolone 40 mg/day. Lille index was used as treatment response criterion. Following statistical criteria were used for data processing: χ2, Wilcoxon, Mann-Whitney, Kaplan – Mayer method.Results. At comparison of treatment efficacy (р=0,810) and short-term survival rate (р=0,857) no significant differences were obtained. At treatment safety analysis in the first group adverse events (AE) were registered in 23,5% of cases (in 4 of 17 patients), in the second group – in 70% (in 14 of 20 patients, р=0,011). Hepatorenal syndrome was significantly more frequent in the second group (р=0,033).Conclusions. Short-time survival in budesonide and prednisolone group does not differ significantly. At application of prednisolone frequency of AE is higher as a whole, particularly – hepatorenal syndrome. |
| format | Article |
| id | doaj-art-067a057e0c8349c6bc57d140348cce2b |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2013-09-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-067a057e0c8349c6bc57d140348cce2b2025-02-10T16:14:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732013-09-012343744801Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trialI. I. Komkova0M. V. Mayevskaya1V. T. Ivashkin2State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationAim of investigation. To determine efficacy and safety of budesonide and prednisolone at alcoholinduced hepatitis (AH) of severe course on development of inflammation and results of the functional hepatic tests, to estimate treatment response and short-term survival rate of patients.Material and methods. Original study included 37 patients with acute AH, that have been selected from 3 medical centers and randomized in two groups. The first group included 17 patients (7 men, 10 women, mean age 46,53±11,01 years). Median of daily alcohol dose was 77 g; 25th and 75th percentiles were 55 and 96 g; duration of intake 13,41±8,55 years. Mean Maddrey index (MI) was 65,22 (37,2 to 145,4). The second group included 20 patients (16 men, 4 women, mean age was 46,5±11,89 years). A median of used alcohol consumption was 70,55 g/day (25th 75th percentiles were 37 and 88 g), duration of intake — 16,85±13,32 years. Mean MI – 58,11 (32,1 to 121,7). Groups were comparable for main clinical and laboratory features. In the first group oral budesonide 9 mg/day per os was applied, in the second – oral prednisolone 40 mg/day. Lille index was used as treatment response criterion. Following statistical criteria were used for data processing: χ2, Wilcoxon, Mann-Whitney, Kaplan – Mayer method.Results. At comparison of treatment efficacy (р=0,810) and short-term survival rate (р=0,857) no significant differences were obtained. At treatment safety analysis in the first group adverse events (AE) were registered in 23,5% of cases (in 4 of 17 patients), in the second group – in 70% (in 14 of 20 patients, р=0,011). Hepatorenal syndrome was significantly more frequent in the second group (р=0,033).Conclusions. Short-time survival in budesonide and prednisolone group does not differ significantly. At application of prednisolone frequency of AE is higher as a whole, particularly – hepatorenal syndrome.https://www.gastro-j.ru/jour/article/view/1219alcohol-induced hepatitis of severe coursebudesonideprednisolonehepatorenal syndrome |
| spellingShingle | I. I. Komkova M. V. Mayevskaya V. T. Ivashkin Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial Российский журнал гастроэнтерологии, гепатологии, колопроктологии alcohol-induced hepatitis of severe course budesonide prednisolone hepatorenal syndrome |
| title | Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial |
| title_full | Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial |
| title_fullStr | Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial |
| title_full_unstemmed | Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial |
| title_short | Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial |
| title_sort | budesonide in treatment of alcohol induced severe hepatitis results of randomized trial |
| topic | alcohol-induced hepatitis of severe course budesonide prednisolone hepatorenal syndrome |
| url | https://www.gastro-j.ru/jour/article/view/1219 |
| work_keys_str_mv | AT iikomkova budesonideintreatmentofalcoholinducedseverehepatitisresultsofrandomizedtrial AT mvmayevskaya budesonideintreatmentofalcoholinducedseverehepatitisresultsofrandomizedtrial AT vtivashkin budesonideintreatmentofalcoholinducedseverehepatitisresultsofrandomizedtrial |